New drug targets 'Undruggable' cancer mutations in first human test
NCT ID NCT05578092
Summary
This was an early safety study testing a new oral drug called MRTX0902, both alone and combined with another cancer drug (adagrasib), in people with advanced solid tumors that have specific genetic mutations in the KRAS pathway. The main goals were to find safe doses and see how the body processes the drug. The study was terminated and enrolled 64 participants with cancers like lung or colorectal cancer that had spread and had no other curative treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 001-101
Nashville, Tennessee, 37203, United States
-
Local Institution - 001-102
Nashville, Tennessee, 37203, United States
-
Local Institution - 001-103
Baltimore, Maryland, 21287, United States
-
Local Institution - 001-104
Fairfax, Virginia, 22031, United States
-
Local Institution - 001-105
Seattle, Washington, 98109, United States
-
Local Institution - 001-106
Cincinnati, Ohio, 45219-2364, United States
-
Local Institution - 001-107
Houston, Texas, 77030, United States
-
Local Institution - 001-108
New Haven, Connecticut, 06520, United States
-
Local Institution - 001-109
Portland, Oregon, 97239-3011, United States
-
Local Institution - 001-110
Rochester, Minnesota, 55905-0001, United States
-
Local Institution - 001-111
Orlando, Florida, 32827-7400, United States
-
Local Institution - 001-112
Dallas, Texas, 75246-2003, United States
-
Local Institution - 001-114
Rio Piedras, 00935, Puerto Rico
-
Local Institution - 001-115
Hackensack, New Jersey, 07601-2191, United States
-
Local Institution - 001-116
Pittsburgh, Pennsylvania, 15232, United States
-
Local Institution - 001-119
Newark, Delaware, 19713-2055, United States
-
Local Institution - 001-122
Fort Worth, Texas, 76104-2154, United States
-
Local Institution - 001-123
Tyler, Texas, 75708-3154, United States
Conditions
Explore the condition pages connected to this study.